DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07073417

Active not recruitingPhase 2

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity

Assets

Ecnoglutide (XW003) / Semaglutide

Listed sites

1

Recruiting sites

—

Enrollment

163

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07073417
Org study IDSCW0502-1122

Timeline

Milestones

Study first posted2025-07-18actual
Study start2025-07-28actual
Last update posted2026-04-13actual
Primary completion2027-02-27estimated
Study completion2027-08-23estimated

Assets

Investigational agents

Ecnoglutide (XW003)Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women.
•Weight change of less than 5% within 3 months prior to screening (self-reported).

Exclusion criteria

•Diagnosis of obesity due to endocrine disorders or a single gene mutation, including but not limited to hypothalamic obesity, pituitary obesity, Cushing's syndrome, hypothyroidic obesity (except for those with normal thyroid function at screening and expected to remain unchanged throughout the trial period after at least 3 months of thyroid hormone replacement therapy), insulinoma, acromegaly.
•History of bariatric surgery or planning to undergo bariatric surgery or use other weight-loss drugs or devices during the trial (except acupuncture for weight loss, liposuction, or abdominal fat removal for more than one year before screening; Except the removal or expulsion of the airbag in the stomach for more than 1 year before screening.
•Diagnosis with any type of diabetes (except gestational diabetes).
•Have used any weight-loss drugs, hypoglycemic drugs, or drugs that may cause significant weight gain within 3 months prior to screening.
•History of acute or chronic pancreatitis or pancreatic injury, history of symptomatic gallbladder disease (except cholecystectomy).
•History of clinically significant gastric emptying abnormalities, such as gastroparesis or gastric outlet obstruction.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

6 endpoints
Primary/protocol endpoint

Percentage change in body weight relative to baseline

Time frame:week 48

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Proportions of participants with weight loss ≥5% from baseline

Time frame:week 48

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Proportions of participants with weight loss ≥10% from baseline

Time frame:week 48

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Proportions of participants with weight loss ≥15% from baseline

Time frame:week 48

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

The change in waist circumference relative to the baseline

Time frame:week 48

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Changes in body mass index (BMI) relative to baseline

Time frame:week 48

BMI, change

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.